Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2020-03-10 07:00:06
Oslo, Norway, 10 March 2020 Financial calendar for Nordic Nanovector ASA FINANCIAL YEAR 2019 27.03.2020 - Annual Report FINANCIAL YEAR 2020 27.08.2020 - Half-yearly Report 30.04.2020 - Annual General Meeting 26.05.2020 - Quarterly Report - Q1 19.11.2020 - Quarterly Report - Q3 For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson) Tel: +44 203 926 8535 Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com. This information is published pursuant to the requirements set out in the Continuing obligations.